Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of 34% ORR of 54% and CR/Partial Response (PR) of 8% in HMA failed patients Median duration of response for the HMA naïve
Conference Call Today at 9:00 a.m. Eastern Time NEWTOWN, Pa., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) , a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer, with a primary focus on
Dr. Woodman is appointed CMO and Senior Vice President of Research & Development, joining Onconova after multiple accomplishments at Novartis Other recent hires in Clinical and Regulatory Affairs strengthen the Onconova team for the advancement of the clinical development of Rigosertib NEWTOWN,
Oral presentation on Saturday will feature efficacy and safety data from Expanded Phase 2 trial of rigosertib in combination with Azacitidine Three Poster presentations to feature pharmacokinetics, dose optimization, and biomarker studies NEWTOWN, Pa., Nov.
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, November 13, 2018 NEWTOWN, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
NEWTOWN, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Dr.
Granted claims cover both oral and injectable formulations of Rigosertib Newly issued US patent 10,098,862 extends protection for Rigosertib into 2037 Equivalent coverage is being sought worldwide and, if granted, will expand intellectual property protection for Rigosertib in additional countries
NEWTOWN, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company will
Reverse split intended primarily to increase the per share bid price of Onconova's common stock and satisfy the Nasdaq Capital Market continued listing requirement NEWTOWN, Pa. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a Phase 3
NEWTOWN, Pa. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company will
